Pink SheetA Trump Administration aligned think tank outlined policies that could use US Centers for Medicare and Medicaid Services and US Trade Representative authorities to pressure foreign governments to incr
Pink SheetAn international pilot that allowed companies to have their applications for increasing drug manufacturing capacity to be simultaneously evaluated by multiple regulatory authorities has yielded positi
ScripSanofi’s multiple sclerosis candidate tolebrutinib is in line for a potential US approval in the autumn after the Food and Drug Administration agreed to a speedy review of the oral Bruton’s tyrosine k
ScripPfizer’s recent exit from gene therapies was not an indictment of the safety and efficacy of gene and cellular therapies. Rather it was the latest example of the difficulties in commercializing these